To examine whether To examine whether high coronary risk patients in Australia, where
use of lipid-lowering drugs (LLD) is very high by international standards, are
receiving LLD.

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian
rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD
(cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage.

Schizophrenia is a mental health disorder characterised by hallucinations, delusions and disorganised behaviour. The Australian pharmaceutical benefits scheme (PBS) reimburse a number of antipsychotic therapies, however, there is little known around the patterns of utilisation and the patient characteristics of these options. Objective: To describe the antipsychotic treatment patterns and the time to antipsychotic switch.

Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic dis-
ease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment).

To study treatment persistence and mortality using a single-pill, fixed-dose combination
tablet compared with a two-pill combination for hypertension.